Skip to Content

Join the 'Arava' group to help and get support from people like you.

Arava News

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Imuran, Xolair, Orencia, Chronic Kidney Disease, Revlimid, Arava, Leflunomide, Azathioprine, Afinitor, Tecfidera, Mycophenolate Mofetil, Peritoneal dialysis, Aubagio, Benlysta

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead researcher Dr. Sebastien Viatte, a research fellow at the University of Manchester in England. Using data from several sources on thousands of patients in the United Kingdom, researchers found that gene mutations at a location on a chromosome called HLA-DRBl were associated with rheumatoid arthritis severity and the response to treatment with tumor necrosis factor (TNF) inhibitor drugs. This study, Viatte said, is a potentially important first step toward personalized medicine for patients with the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Rituximab, Orencia, Cimzia, Arava, Leflunomide, Juvenile Rheumatoid Arthritis, Azathioprine, Simponi, Xeljanz, Infliximab

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by Drugs.com

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – which include drugs such as adalimumab (Humira), anakinra (Kineret) and etanercept (Enbrel) – have allowed patients to gain better control of rheumatoid arthritis when taken early in the course of disease, the researchers explained. But some of the new drugs top $20,000 annually, according to the April 21 online report in the journal Arthritis & Rheumatology. "Many patients face a growing and unacceptable financial burden for access to treatment," said study lead author Dr. Jinoos Yazdany of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Orencia, Rituximab, Arava, Leflunomide, Azathioprine, Xeljanz, Infliximab, Adalimumab, Etanercept, Apremilast

FDA Drug Safety Communication: New Boxed Warning for Severe Liver Injury with Arthritis Drug Arava (leflunomide)

Posted 14 Jul 2010 by Drugs.com

Safety Announcement Additional Information for Patients Additional Information for Healthcare Professionals Data Summary   Safety Announcement [07-13-2010] The U.S. Food and Drug Administration (FDA) is adding information on severe liver injury to the Boxed Warning of Arava (leflunomide) – a drug used to treat rheumatoid arthritis - to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced. FDA previously required a Boxed Warning stating that leflunomide was contraindicated in pregnant women, or women of childbearing potential who were not using reliable contraception.   The information on severe liver injury now being added to the Boxed Warning states: Patients with pre-existing liver disease should not receive leflunomide. Patients with elevated liver enzymes (ALT greater than two times the upper limit of normal) should not receive l ... Read more

Related support groups: Arava

FDA Medwatch Alert: Arava (leflunomide)

Posted 20 Nov 2003 by Drugs.com

Aventis Pharmaceuticals and FDA updated the prescribing information for Arava (leflunomide), indicated for the treatment of active rheumatoid arthritis. In postmarketing experience worldwide, rare, serious hepatic injury, including cases with fatal outcome, have been reported during treatment with Arava. Most cases occurred within 6 months of therapy and in a setting of multiple risk factors for hepatotoxicity. Rare postmarketing reports of severe infections, including sepsis, which may be fatal, were also received. Most of the reports were confounded by concomitant immunosuppressant therapy and/or comorbid illness, which, in addition to rheumatoid disease, may predispose patients to infection. [October, 2003 Letter - Aventis][June, 2003 Revised, highlighted label - Aventis] Read more

Related support groups: Arava

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis

Arava Patient Information at Drugs.com